Kerri FitzgeraldMantle Cell Lymphoma | October 5, 2022
Event-free survival at 24 months may become an important clinical endpoint in mantle cell lymphoma in the future.
Read More
Kerri FitzgeraldMyelodysplastic Syndromes | October 4, 2022
A study showed "unexpected" results related to race and MDS survival...
Kerri FitzgeraldAcute Myeloid Leukemia | October 3, 2022
The efficacy of enasidenib in patients with AML depends on the mutation type.
Kerri FitzgeraldAggressive B-Cell Lymphoma | September 13, 2022
The addition of brentuximab vedotin improved survival in Hodgkin lymphoma.
Cecilia BrownAggressive B-Cell Lymphoma | August 8, 2022
A new model that makes use of a promising imaging biomarker can predict diffuse large B-cell lymphoma relapse and survival ...
Leah SherwoodAcute Myeloid Leukemia | June 29, 2022
The expression patterns and clinical significances of CD300s in cancers are still not well understood.
Editorial Board